| This is the talk page for discussing improvements to the Fasudil article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Fasudil.
|
Sygnis Pharma AG has the distribution rights for that class of drugs.
Memory Alzheimer's study by ASU and the Translational Genomics Research Institute published in the journal Behavioral Neuroscience. Dr. Matthew Huentelman, a TGen scientist and the paper's first author.
Fasudil is used in Japan to aid stroke victims by improving blood flow to the brain.
Information from an article on azcentral.com
http://www.azcentral.com/business/articles/2009/02/01/20090201biz-memory0202.html —Preceding unsigned comment added by Qqtpie (talk • contribs) 14:57, 2 February 2009 (UTC)
Inhibitor of Dkk1 edit
New research may answer why many recent Alzheimer's clinical trials have failed mentions its use as an experimental inhibitor of Dkk1 in mice. - Rod57 (talk) 17:29, 29 September 2018 (UTC)
Clinical trials edit
Would be nice to see a summary of the clinical trials supporting the approval in Japan & China. - And have any been done in in USA/EU/Australia ? - Rod57 (talk) 17:29, 29 September 2018 (UTC)